Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-NODAGA-SNA018
- Development stage
- Unknown
- Lead developer
- SmartNuclide
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
68Ga-NODAGA-SNA018 is a radiolabeled diagnostic imaging agent designed for positron emission tomography (PET/CT) to detect and characterize breast cancer lesions. The probe consists of the SNA018 nanobody, a single-domain antibody fragment that binds with high affinity and specificity to the Human Epidermal Growth Factor Receptor 2 (HER2), which is frequently overexpressed in breast cancer. This targeting moiety is conjugated to the chelator NODAGA (1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid) and labeled with the positron-emitting radioisotope Gallium-68 (68Ga). Due to its small molecular size, the nanobody probe exhibits rapid blood clearance and high tumor penetration, allowing for high-contrast imaging of HER2 expression shortly after administration. It is currently being evaluated in clinical trials to assess its diagnostic accuracy and biodistribution in patients with breast cancer.
- Other names
- [68Ga]Ga-NODAGA-SNA018Gallium-68 NODAGA-SNA018Gallium68 NODAGA-SNA018Gallium 68 NODAGA-SNA018
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on 68Ga-NODAGA-SNA018.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-NODAGA-SNA018.